We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+14.02%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.23B
AUM Growth
+$101M
Cap. Flow
-$21.8M
Cap. Flow %
-1.78%
Top 10 Hldgs %
30.12%
Holding
96
New
14
Increased
27
Reduced
30
Closed
13

Top Buys

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$23.4M
2
ABBV icon
AbbVie
ABBV
+$21.1M
3
JNJ icon
Johnson & Johnson
JNJ
+$17M
4
MRK icon
Merck
MRK
+$14.7M
5
CVS icon
CVS Health
CVS
+$11.7M

Top Sells

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$39.6M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$25.9M
3
LVGO
Livongo Health, Inc. Common Stock
LVGO
+$23.4M
4
IMMU
Immunomedics Inc
IMMU
+$18.8M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.59%
2 Industrials 0.53%
3 Communication Services 0%
4 Consumer Discretionary 0%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
26
Regeneron Pharmaceuticals
REGN
$83.2B
$19.3M 1.58%
40,000
+17,500
+78% +$9.45M
BSX icon
27
Boston Scientific
BSX
$73.1B
$19.1M 1.55%
530,000
+80,000
+18% +$2.88M
ALXN
28
DELISTED
Alexion Pharmaceuticals
ALXN
$18.7M 1.53%
120,000
-100,000
-45% -$12.9M
JNJ icon
29
Johnson & Johnson
JNJ
$631B
$18.1M 1.48%
+115,000
New +$17M
CNC icon
30
Centene
CNC
$32.9B
$17.1M 1.4%
285,000
-15,000
-5% -$953K
BAX icon
31
Baxter International
BAX
$14.4B
$16.4M 1.34%
205,000
+50,000
+32% +$3.96M
ABT icon
32
Abbott
ABT
$188B
$16.4M 1.34%
150,000
-55,000
-27% -$5.98M
ITCI
33
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$15.9M 1.3%
500,000
+25,000
+5% +$657K
APLS
34
DELISTED
Apellis Pharmaceuticals
APLS
$15.4M 1.26%
270,000
+45,000
+20% +$1.9M
ESPR
35
DELISTED
Esperion Therapeutics
ESPR
$15.4M 1.26%
592,225
+137,225
+30% +$4.11M
IOVA icon
36
Iovance Biotherapeutics
IOVA
$2.9B
$14.8M 1.21%
320,000
-20,000
-6% -$794K
ALNY icon
37
Alnylam Pharmaceuticals
ALNY
$29B
$14.5M 1.18%
111,700
+11,700
+12% +$1.56M
NBIX icon
38
Neurocrine Biosciences
NBIX
$16.8B
$14.4M 1.17%
150,000
+75,000
+100% +$7.24M
MGNX icon
39
MacroGenics
MGNX
$259M
$14.3M 1.17%
625,000
-10,711
-2% -$247K
SGMO
40
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$12.8M 1.05%
821,888
+146,888
+22% +$1.72M
TMO icon
41
Thermo Fisher Scientific
TMO
$222B
$12.8M 1.04%
27,450
-2,550
-9% -$1.2M
LIVN icon
42
LivaNova
LIVN
$4.21B
$12.6M 1.03%
190,000
-20,000
-10% -$1.11M
RPRX icon
43
Royalty Pharma
RPRX
$25.8B
$12.5M 1.02%
+250,000
New +$10.6M
HCA icon
44
HCA Healthcare
HCA
$89.6B
$12.3M 1.01%
75,000
– –
AERI
45
DELISTED
Aerie Pharmaceuticals
AERI
$11.5M 0.94%
850,000
– –
EW icon
46
Edwards Lifesciences
EW
$53B
$11.4M 0.93%
125,000
+5,000
+4% +$415K
SGEN
47
DELISTED
Seagen Inc. Common Stock
SGEN
$11.4M 0.93%
65,000
-5,000
-7% -$932K
XNCR icon
48
Xencor
XNCR
$1.6B
$11.3M 0.92%
259,341
-659
-0.3% -$27.3K
BDX icon
49
Becton Dickinson
BDX
$48.9B
$11.3M 0.92%
46,125
+10,250
+29% +$2.39M
ZBH icon
50
Zimmer Biomet
ZBH
$18.7B
$10M 0.82%
66,950
-17,510
-21% -$2.47M
1
2
3 4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2020 Portfolio in Review

As of Q4 2020, Rhenman & Partners Asset Management held 96 positions worth $1.23B, up 9% from $1.12B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rhenman & Partners Asset Management's Q4 2020 filing shows 14 new, 27 increased, 30 reduced and 13 closed positions. Its largest new stake was Teladoc Health: 115,000 shares worth $23M. The largest sale was NovoCure, an estimated $39.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Industrials and Communication Services.

  • Rhenman & Partners Asset Management's largest Q4 2020 buy was Teladoc Health: 115,000 shares worth $23M.
  • Rhenman & Partners Asset Management added most to AbbVie in Q4 2020, an estimated $21.1M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2020 reduction was NovoCure, cutting an estimated $39.6M.
  • Rhenman & Partners Asset Management fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $25.9M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 30% of its $1.23B portfolio in Q4 2020.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 13 in Q4 2020.
  • Rhenman & Partners Asset Management's portfolio value rose 9% quarter-over-quarter to $1.23B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2020, filed 19 Jan 2021.